Developing an ESG strategy and a supply chain assessment system
Neopharmed
The context
The objectives
Circularity's intervention
The results
Neopharmed
Neopharmed Gentili S.p.A. is one of the leading Italian pharmaceutical companies.
Specialized in the development of high-value therapeutic solutions, the company is passionately dedicated to health and longevity, combining scientific rigor with patient-focused care.
The context
In a regulated and sensitive sector such as pharmaceuticals, responsibility is a prerequisite.
Neopharmed has chosen to raise its standards by systematically integrating ESG criteria into its corporate management, with a particular focus on the ethical and environmental qualification of its suppliers and partners.
The objectives
Structuring a three-year Strategic Plan and a supply chain monitoring system to ensure transparency and operational resilience.
Circularity's intervention
Our support focused on building solid and pervasive sustainability governance:
Pharmaceutical Materiality Analysis: We mapped the specific impacts of the sector, from chemical waste management to ethics in research, defining priorities for the business and for health stakeholders.
ESG Supply Chain Risk Management: We implemented an assessment protocol for suppliers, analyzing their environmental and social performance to ensure a value chain consistent with Neopharmed's principles.
Operational Plan Development: We defined short and medium-term objectives, integrating ESG targets into management decision-making processes.
The results
-
Supply Chain Control: Reduced reputational and operational risks thanks to a monitored supply chain.
-
Solid ESG Rating: Greater appeal to institutional and financial stakeholders.
-
Culture of Sustainability: Full internal awareness of the social and environmental value generated by pharmaceutical activity.
Enhance your ESG commitment
With Circularity by your side, it's easier.